Scarica l'app Stockscreener
6.915
3.11%
-0.155
Precedente Chiudi:
$7.07
Aprire:
$6.9
Volume 24 ore:
4,058
Relative Volume:
0.01
Capitalizzazione di mercato:
$468.26M
Reddito:
-
Utile/perdita netta:
$-122.44M
Rapporto P/E:
-3.0679
EPS:
-2.254
Flusso di cassa netto:
$-103.79M
1 W Prestazione:
-5.06%
1M Prestazione:
-31.70%
6M Prestazione:
+5.55%
1 anno Prestazione:
+47.00%
Intervallo 1D:
$6.84
$7.055
Intervallo di 1 settimana:
$6.71
$7.50
Portata 52W:
$2.65
$12.25
Engene Holdings Inc Stock (ENGN) Company Profile
Nome
Engene Holdings Inc
Settore
Industria
Telefono
(514) 332-4888
Indirizzo
4868 RUE LEVY, SUITE 220, SAINT-LAURENT
Compare ENGN vs VRTX, REGN, ALNY, ARGX, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ENGN
Engene Holdings Inc
|
6.99 | 473.62M | 0 | -122.44M | -103.79M | -2.254 |
VRTX
Vertex Pharmaceuticals Inc
|
451.39 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
754.55 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
329.82 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
687.64 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
147.26 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Engene Holdings Inc Stock (ENGN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-30 | Iniziato | Jefferies | Buy |
| 2025-11-11 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2025-02-18 | Iniziato | Piper Sandler | Overweight |
| 2025-02-14 | Downgrade | UBS | Buy → Neutral |
| 2024-12-23 | Iniziato | H.C. Wainwright | Buy |
| 2024-11-27 | Iniziato | Raymond James | Outperform |
| 2024-11-18 | Iniziato | JMP Securities | Mkt Outperform |
| 2024-08-28 | Iniziato | Oppenheimer | Outperform |
| 2024-04-22 | Iniziato | Wells Fargo | Overweight |
| 2024-04-15 | Iniziato | Guggenheim | Buy |
| 2024-03-28 | Iniziato | UBS | Buy |
| 2024-03-08 | Iniziato | Morgan Stanley | Overweight |
| 2024-02-20 | Iniziato | Leerink Partners | Outperform |
Mostra tutto
Engene Holdings Inc Borsa (ENGN) Ultime notizie
Energy Moves: Is enGene Holdings Inc Equity Warrant impacted by rising ratesMarket Sentiment Review & Precise Trade Entry Recommendations - baoquankhu1.vn
Sentiment Watch: Is enGene Holdings Inc Equity Warrant stock a value trapPortfolio Update Report & Technical Confirmation Trade Alerts - baoquankhu1.vn
AI Stocks: What analysts say about enGene Holdings Inc Equity Warrant stockMarket Activity Report & Verified Chart Pattern Signals - baoquankhu1.vn
UBS cuts Engene Holdings stock price target on trial costs - Investing.com UK
Volume Recap: Can enGene Holdings Inc Equity Warrant lead its sector in growth2026 Support & Resistance & Long Hold Capital Preservation Tips - baoquankhu1.vn
Bank Watch: Is enGene Holdings Inc a stock for growth or value investors2026 Short Interest & Weekly Consistent Profit Watchlists - baoquankhu1.vn
Sell Signal: How does enGene Holdings Inc compare to its peersQuarterly Risk Review & Verified Momentum Stock Alerts - baoquankhu1.vn
Valuation Update: What analysts say about enGene Holdings Inc Equity Warrant stock2026 Snapshot & Real-Time Volume Trigger Notifications - baoquankhu1.vn
Bank Watch: Is enGene Holdings Inc Equity Warrants ROE strong enough2026 Sector Review & Verified Momentum Stock Alerts - baoquankhu1.vn
ENGN PE Ratio & Valuation, Is ENGN Overvalued - Intellectia AI
Combination Therapies Reshape Oncology: A $748B Market Shifts Standard of Care - The Globe and Mail
enGene CEO Pitches Detalimogene as Community-Friendly NMIBC Option, Teases Q2 LEGEND Data Update - MarketBeat
enGene Shares Detalimogene NMIBC Trial Changes, FDA Endpoint Shift, and 2027 Approval Path at Conference - MarketBeat
Portfolio Update: Is enGene Holdings Inc stock a good dividend stock2026 Performance Recap & Community Trade Idea Sharing Platform - baoquankhu1.vn
Aug Reactions: Why is enGene Holdings Inc Equity Warrant stock going up2026 EndofYear Setup & Real-Time Volume Analysis Alerts - baoquankhu1.vn
Short Interest in enGene Holdings Inc. (NASDAQ:ENGN) Decreases By 17.7% - MarketBeat
enGene Highlights 2026 Data Catalysts, BLA Plans for Bladder Cancer Gene Therapy at Barclays Conference - MarketBeat
Braidwell LP Invests $15.48 Million in enGene Holdings Inc. $ENGN - MarketBeat
enGene (NASDAQ:ENGN) Upgraded to "Hold" at Wall Street Zen - MarketBeat
Oppenheimer Issues Pessimistic Forecast for enGene (NASDAQ:ENGN) Stock Price - Defense World
Merger Talk: Can enGene Holdings Inc Equity Warrant lead its sector in growth2026 Key Highlights & Reliable Price Action Trade Plans - baoquankhu1.vn
AI Stocks: Will enGene Holdings Inc stock benefit from M A2026 Short Interest & Entry and Exit Point Strategies - baoquankhu1.vn
enGene Holdings: Key Catalysts Incoming For 2026 (NASDAQ:ENGN) - Seeking Alpha
enGene (NASDAQ:ENGN) Sees Unusually-High Trading VolumeShould You Buy? - MarketBeat
Citizens reiterates Engene Holdings stock rating on BLA timeline By Investing.com - Investing.com South Africa
HC Wainwright Has Optimistic Outlook of enGene Q2 Earnings - MarketBeat
Citizens reiterates Engene Holdings stock rating on BLA timeline - Investing.com
FY2030 Earnings Forecast for enGene Issued By HC Wainwright - Defense World
enGene Shares Gain 5% After Bladder Cancer Therapy Shows Stronger Response Rates - MSN
enGene (NASDAQ:ENGN) Price Target Lowered to $30.00 at Oppenheimer - MarketBeat
Pullback Watch: How does enGene Holdings Inc compare to its peers2026 Highlights & Weekly High Return Opportunities - baoquankhu1.vn
ENGN: Detalimogene offers promising efficacy and convenience for NMIBC, with pivotal data updates ahead - TradingView
HC Wainwright Has Positive Outlook of enGene FY2030 Earnings - MarketBeat
enGene Holdings (ENGN) Gets a Buy from Wells Fargo - The Globe and Mail
Smart Money: Can SIFCO Industries Inc continue delivering strong returns2026 Momentum & Stepwise Trade Signal Guides - baoquankhu1.vn
ENGN: Detalimogene's pivotal data and unique profile position it to transform NMIBC treatment - TradingView
enGene (NASDAQ:ENGN) Posts Earnings Results, Beats Estimates By $0.11 EPS - MarketBeat
ENGN: Detalimogene offers a unique, highly tolerable NMIBC therapy with pivotal data updates in 2024 - TradingView
Engene stock price target lowered to $27 by Guggenheim on estimates By Investing.com - Investing.com India
Engene stock price target lowered to $27 by Guggenheim on estimates - Investing.com Australia
enGene Reports Q1 2026 Results, Advances Detalimogene for Bladder Cancer with Strong Cash Position and FDA Milestones 12 - Minichart
Raymond James Maintains Strong Buy on ENGN enGene Holdings Inc March 2026 - Meyka
enGene Holdings Inc. Q1 2026 Quarterly Report: Financial Statements, Management Discussion & Key Disclosures - Minichart
enGene Holdings Inc. Announces Sales Agreement with Leerink Partners LLC for At-the-Market Offering of Common Shares - Minichart
enGene (NASDAQ:ENGN) Shares Gap DownHere's Why - MarketBeat
Raymond James reiterates Engene Holdings stock Strong Buy rating By Investing.com - Investing.com South Africa
ENGN: Detalimogene achieves 62% 6-month CR rate in NMIBC with strong safety and operational advantages - TradingView
HC Wainwright Reiterates 'Buy' Rating for enGene Holdings (ENGN) - GuruFocus
enGene's (ENGN) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat
EnGene Holdings Inc. Reports Earnings Results for the First Quarter Ended January 31, 2026 - marketscreener.com
Raymond James reiterates Engene Holdings stock Strong Buy rating - Investing.com
Engene Holdings Inc Azioni (ENGN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.99%
3.03%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):